X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardiovascular disease, central nervous system diseases and cystic fibrosis.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $93.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardiovascular disease, central nervous system diseases and cystic fibrosis.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $93.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 08, 2024
Details:
The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardiovascular disease, central nervous system diseases and cystic fibrosis.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $86.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 05, 2024
Details:
Company plans to nominate additional therapeutic targets to its proprietary genetic medicines pipeline, fueled by its automated discovery engine and versatile gene editing toolbox, to expand into additional preclinical proof-of-concept studies.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 05, 2023
Details:
CRISPR gene editing is a technology that modifies the sequence of DNA in cells utilizing a specific RNA-guided nuclease (Cas enzyme). Gene editing enzymes act as molecular word processors to correct the genetic code at the precise spot where it is malfunctioning.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ionis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $80.0 million
Deal Type: Collaboration November 14, 2022
Details:
The partnership will leverage Metagenomi’s proprietary gene editing systems to complement Affini-T’s state-of-the-art TCR discovery and synthetic biology platforms to generate groundbreaking cell therapy products including AFNT-111.
Lead Product(s): AFNT-111
Therapeutic Area: Oncology Product Name: AFNT-111
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Affini-T Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 15, 2022
Details:
CRISPR-associated gene-editing systems (Immuno-Oncology (TCR)- Solid tumor) discovered in metagenomic samples enable efficient genome engineering in multiple primary immune cell types.
Lead Product(s): TCR-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies to accelerate the development of in vivo gene editing therapeutics.
Lead Product(s): In-vivo Gene Editing Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
